Skip to content
Search AI Powered

Latest Stories

This New Agreement Between 23andMe and GlaxoSmithKline Pharmaceuticals Is Causing Major Concern Among Privacy Advocates

This New Agreement Between 23andMe and GlaxoSmithKline Pharmaceuticals Is Causing Major Concern Among Privacy Advocates

The future that TED Talks have long promised is one step closer to reality.

The future that TED Talkshavelongpromised is one step closer to reality, thanks to a new deal between pharmaceutical giant GlaxoSmithKline (GSK) and home DNA-testing kit service 23andMe.

The four-year agreement will grant GSK exclusive access to 23andMe’s database of genetic information, with the goal of developing new, targeted drugs and therapies. This isn’t the first time that 23andMe has offered its customers’ data to another organization for research, but those partnerships have previously been transparent. What does this new deal mean for genetic privacy and who will benefit from the partnership?


To privacy advocates,there’s little more alarming than the sale of genetic information. The data could be used by insurance companies to identify certain genetic markers as high-risk, leading to increased premiumseven decades after the test is performed. Law enforcement could subpoena the data from 23andMe (or any other genetic testing company) without informing the customers and without their consent. Thelaw surrounding questions of genetic privacy and ownership are in their infancy. And no genetic testing company canensure that your genetic information remains private.

But in this case, the most serious issue seems to be profit. 23andMe’s estimated 5 million customers can choose to opt out of having their DNA used in research. Those who don’t opt out have essentially donated their genome to science. But that munificence is one-sided: whatever drugs or treatments are developed using the customers’ genetic information will be sold by GSK or 23andMe for profit.

And there’s certainly profit to be made. Separate from this deal, GSK has invested $300 million in 23andMe. It’s a relative bargain for GSK, because 23andMe’s database is up to 10 times larger than other available databases, and its customers have already paid for partial sequencing — typically a major expense.

For its part, GSK is confident that the partnership will produce effective treatments, which will benefit patients across the world. To begin, they’re focusing on treatments for Parkinson’s disease based on a gene called LRRK2 that is mutated in some Parkinson’s patients.

“When you get a genetically validated target and you pursue it, it’s twice as likely to end up being a medicine,” said GSK chief science officer Hal Barron.

Previously, 23andMe had been carrying out some genetic research itself, in partnership with the National Institutes of Health (NIH)  and University of California, Los Angeles and University of Southern California.In those cases, customers could see a clear benefit in allowing research to be carried out on their genome. Just by allowing the company to use the material that the customer had already given, they felt like part of a larger solution.

“It’s one thing for NIH to ask people to donate their genome sequences for the higher good,” Peter Pitts, president of the Center for Medicine in the Public Interest, told NBC News. “But when two for-profit companies enter into an agreement where the jewel in the crown is your gene sequence and you are actually paying for the privilege of participating, I think that’s upside-down.”

More from News

Screenshot of Nick Fuentes
America First

White Nationalist Admits That Liberals Were Right About Trump Being A 'Demagogue'

Far-right pundit and white nationalist Nick Fuentes admitted on his show that "liberals were right, fundamentally" about President Donald Trump, acknowledging Trump's brand of authoritarian populism by referring to him as a "populist demagogue."

In its modern sense, a demagogue is a political agitator who seeks to advance their political goals or personal power by appealing to people’s emotions, prejudices, and hardships.

Keep ReadingShow less
scene from Disney's Pocahontas
Disney

'Based On A True Story' Movies That Aren't True At All

The entertainment industry has long been criticized for their creative license when it comes to retelling history or anything "based on a true story."

Going back to the silent film era and D.W. Griffith's ridiculously inaccurate White supremacist propaganda Birth Of A Nation to Mel Gibson's Braveheart to Disney's Pocahontas, some films go way beyond creative license and careen into total malarkey.

Keep ReadingShow less
A person holding a fan of cash.
person holding fan of U.S. dollars banknote

People Describe The Moment They Realized They Were Privileged

There is little more off-putting than when people flaunt their wealth and privilege in other people's faces.

On the flip side, not everyone takes kindly to wealthy people who act like they're "one of us".

Keep ReadingShow less
Elon Musk
Kevin Lamarque/Pool/AFP via Getty Images

Musk's AI Chatbot Throws Republicans Under The Bus After Being Asked About Economy

Grok, billionaire Elon Musk's very own chatbot, threw Republicans under the bus after software engineer Alex Coke asked it if Democrats or Republicans have been better for the economy in the past 30 years, only for it to answer that yes, in fact, Democrats are the winners when it comes to economic policy.

Economic policy is certainly on everyone's minds these days. A new CNN poll conducted by SSRS shows that Americans are not pleased with President Donald Trump’s management of the economy, leaving him with unfavorable ratings on what is considered the nation’s most important issue.

Keep ReadingShow less
Screenshot of Donald Trump
Fox 5 Washington D.C./YouTube

CNN Airs Brutal Reminder Of Trump's Previous Economic Predictions—And They Did Not Age Well

CNN came with the receipts, airing a supercut of clips from 2020 and 2024 of President Donald Trump making hilariously wrong economic predictions—a damning reel of evidence as financial markets decline and investor concerns grow over Trump’s trade policies.

In fact, Trump’s escalating trade war pushed the S&P 500 more than 10% below its record high set just last month. A drop of this size is significant enough that professional investors call it a “correction,” and the S&P 500’s 1.4% decline on Thursday marked its first since 2023.

Keep ReadingShow less